ATM and cutaneous melanoma: However, in the TCGA cohort examined in our study, we found that BRCA mutations are represented in as many as 11.5% of cutaneous melanoma patients, with many patients also harboring mutations to ATM, BRIP1, CHECK2, DMC1, FANCD2, FANCM, and POLQ. As 37.5% of this patient cohort had at least one mutation affecting the HR pathway, the use of these and other mutations warrant consideration when exploring PARP inhibitors in subsequent clinical trials.